Keryx Biopharmaceuticals (KERX) Hits New 52-Week Low at $4.46

Keryx Biopharmaceuticals (NASDAQ:KERX) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $4.46 and last traded at $4.54, with a volume of 1594500 shares trading hands. The stock had previously closed at $4.58.

A number of equities research analysts have issued reports on the company. Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 14th. Stifel Nicolaus cut their target price on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a research note on Wednesday, November 8th. ValuEngine cut Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. Finally, BidaskClub upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $7.35.

The company has a debt-to-equity ratio of 13.95, a current ratio of 4.46 and a quick ratio of 3.76.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $15.00 million for the quarter, compared to analyst estimates of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. Keryx Biopharmaceuticals’s revenue for the quarter was up 138.1% on a year-over-year basis. During the same period last year, the business posted ($0.39) earnings per share. equities research analysts anticipate that Keryx Biopharmaceuticals will post -1.36 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Keryx Biopharmaceuticals by 5.1% during the second quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock valued at $52,043,000 after purchasing an additional 349,521 shares during the period. State Street Corp increased its holdings in shares of Keryx Biopharmaceuticals by 20.1% during the first quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock valued at $21,432,000 after purchasing an additional 582,624 shares during the period. Rice Hall James & Associates LLC increased its holdings in shares of Keryx Biopharmaceuticals by 24.3% during the second quarter. Rice Hall James & Associates LLC now owns 1,666,934 shares of the biopharmaceutical company’s stock valued at $12,052,000 after purchasing an additional 326,285 shares during the period. Northern Trust Corp increased its holdings in shares of Keryx Biopharmaceuticals by 6.9% during the second quarter. Northern Trust Corp now owns 1,089,860 shares of the biopharmaceutical company’s stock valued at $7,881,000 after purchasing an additional 70,420 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Keryx Biopharmaceuticals by 1.1% during the third quarter. Bank of New York Mellon Corp now owns 973,229 shares of the biopharmaceutical company’s stock valued at $6,910,000 after purchasing an additional 10,175 shares during the period. 64.83% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Keryx Biopharmaceuticals (KERX) Hits New 52-Week Low at $4.46” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/09/keryx-biopharmaceuticals-kerx-hits-new-52-week-low-at-4-46.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit